Changing Minds®
A Breakthrough Neuropsychiatry Company
Latest Updates
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
Missed Our
Breakthrough Therapy announcement on
March 13th, 2024?
We’re on a mission to revolutionize mental healthcare.
At Cybin, we’re on a mission to revolutionize mental healthcare by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens to address the unmet needs of patients across a multitude of mental health issues.
We are working with a network of world-renowned partners and pioneers in the field to create safe and effective tryptamine-based therapies. Together, we believe we can discover, develop and commercialize novel therapies that will transform the mental health treatment landscape.
Led by Science
Our strategy is to combine novel molecules with controllable drug delivery systems through our proprietary deuterated process. With our approach, we are engineering next-generation, patent-protected, commercially scalable drug candidates to further evolve mental health treatments.
Novel Second-Generation Therapies based on well-known scaffolds including Psilocin, DMT, MDMA with improved bioavailability.
Developing ground-breaking facilitation training that supports leading clinical approaches to promote supportive healing.
3 active drug programs targeting Major Depressive Disorder (CYB003), Generalized Anxiety Disorder (CYB004) and CNS disorders (CYB005).
220+ patent applications pending
70+ granted patents
Backed by an
Experienced Team
Deep-rooted pharmaceutical and regulatory expertise across psychiatry and drug development. Scientific leadership that includes work in addiction and neuropsychiatry, oversight of 60+ IND programs with the FDA as well as success in developing multiple widely used commercially available prescription drugs.
